Boston Scientific (NYSE: BSX) today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

Few disciplines in medicine have evolved as rapidly as endovascular therapy for arterial and venous disease. In this issue of ...

A discussion of a challenging case of renal artery denervation for resistant hypertension. Hypertension (HTN) is estimated to ...

A recent review of 41 femoral arteriograms carried out at the Memorial Hospital, Worcester, indicated that 76 per cent showed an obstruction of the superficial femoral artery at this level (Fig.

PTAB with the DETOUR System offers a novel approach to treating complex peripheral arterial disease (PAD), enabling physicians to percutaneously bypass lesions in the superficial femoral artery by ...

The treatment of patients with peripheral arterial disease has evolved tremendously since the early 1960s, when Charles Dotter first successfully revascularized a superficial femoral artery ...

ChromaFlo is appropriate for peripheral and coronary vessels, including left main, bifurcations, superficial femoral artery, and iliac. It is designed to make lumen size and stent apposition ...

The principal veins in the superficial system are the great saphenous vein (GSV) and the small saphenous vein (SSV). The GSV runs from the medial ankle to the groin, joining the common femoral ...